Carcinogenesis, Vol. 23, No. 1, 131-142,
January 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol
1 McArdle Laboratory for Cancer Research, Department of Oncology, Room 506A, 1400 University Ave, Madison, WI 53706, USA
2 Present address: Howard Hughes Medical Institute, Department of Cellular and Molecular Medicine, HHMI/CMM-West, Room 219, University of California-San Diego School of Medicine, Mail Code 0686, 9500 Gilman Drive, La Jolla, CA 92093-0686, USA
The monoterpene perillyl alcohol (POH) has preventive and therapeutic effects in a wide variety of pre-clinical tumor models, including those for breast cancers, and is currently being tested in human phase I clinical trials. POH causes both cytostasis and apoptosis in rat mammary carcinomas. In vitro, POH inhibits cellular proliferation in a variety of mammalian cell lines. Here we investigated the mechanisms underlying cytostasis by studying the effects of POH on the cell cycle in vitro using the murine mammary transformed cell line TM6. In TM6 cells, POH causes an early G1 cell-cycle block and slows the G2–M transition. An increase in pRB in its hypophosphorylated state is associated with the early G1 block caused by POH. POH treatment inhibits two important targets in the cells during the G1–S transition: cyclin D1- and cyclin E-associated kinase. POH treatment leads to a reduction in cyclin D1 RNA and protein levels and prevents the formation of active cyclin D1-associated kinase complexes in synchronous cells during the exit of G0 and entry into the cell cycle. In addition, POH treatment induces an increased association of p21WAF1 with cyclin E–Cdk2 complexes, and inhibits the activating phosphorylation of Cdk2. All these effects of POH may contribute to the inhibition of the transition out of the G1 phase of the cell cycle.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Rixe and T. Fojo Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jahangir and S. Sultana Perillyl Alcohol Protects Against Fe-NTA-Induced Nephrotoxicity and Early Tumor Promotional Events in Rat Experimental Model Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Wiseman, S. R. Werner, and P. L. Crowell Cell Cycle Arrest by the Isoprenoids Perillyl Alcohol, Geraniol, and Farnesol Is Mediated by p21Cip1 and p27Kip1 in Human Pancreatic Adenocarcinoma Cells J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Berchtold, K.-S. Chen, S. Miyamoto, and M. N. Gould Perillyl Alcohol Inhibits a Calcium-Dependent Constitutive Nuclear Factor-{kappa}B Pathway Cancer Res., September 15, 2005; 65(18): 8558 - 8566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Loutrari, M. Hatziapostolou, V. Skouridou, E. Papadimitriou, C. Roussos, F. N. Kolisis, and A. Papapetropoulos Perillyl Alcohol Is an Angiogenesis Inhibitor J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 568 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Liston, R. Nines, P. S. Carlton, A. Gupta, R. Aziz, W. Frankel, and G. D. Stoner Perillyl Alcohol as a Chemopreventive Agent in N-Nitrosomethylbenzylamine-induced Rat Esophageal Tumorigenesis Cancer Res., May 15, 2003; 63(10): 2399 - 2403. [Abstract] [Full Text] [PDF]
|
|